Key facts
- It has raised $500K; the latest was Grant ($400K) in Jun 2025.
- Notable investors include Keiretsu Forum, Innovation Works, Accelerator Venture Partners, AlphaLab Health, Casabona Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for MetasTx
- ·The full record, as it builds
Funding rounds
No funding rounds for MetasTx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MetasTx
Operator of a healthcare firm intended to create novel therapies to treat and prevent metastasis of cancer. The company specializes in creating treatments that prevent and treat prostate cancer metastasis without the devastating effects of androgen deprivation therapies, enabling patients with a well-known enzyme to be pivotal in cancer initiation and metastasis and is majorly expressed in prostate, breast, and skin cancers.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2021
- Employees
- 7
- Website
- metastx.com/
- Ownership
- Privately Held (backing)
MetasTx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MetasTx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MetasTx in its N-PORT filings yet. We sweep new filings monthly.